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Abstract
Introduction: Multiple comorbidities among HIV-positive individuals may increase the potential for polypharmacy causing
drug-to-drug interactions and older individuals with comorbidities, particularly those with cognitive impairment, may have diffi-
culty in adhering to complex medications. However, the effects of age-associated comorbidities on the treatment outcomes of
combination antiretroviral therapy (cART) are not well known. In this study, we investigated the effects of age-associated
comorbidities on therapeutic outcomes of cART in HIV-positive adults in Asian countries.
Methods: Patients enrolled in the TREAT Asia HIV Observational Database cohort and on cART for more than six months
were analysed. Comorbidities included hypertension, diabetes, dyslipidaemia and impaired renal function. Treatment outcomes
of patients ≥50 years of age with comorbidities were compared with those <50 years and those ≥50 years without comorbidi-
ties. We analysed 5411 patients with virological failure and 5621 with immunologic failure. Our failure outcomes were defined
to be in-line with the World Health Organization 2016 guidelines. Cox regression analysis was used to analyse time to first
virological and immunological failure.
Results: The incidence of virologic failure was 7.72/100 person-years. Virological failure was less likely in patients with better
adherence and higher CD4 count at cART initiation. Those acquiring HIV through intravenous drug use were more likely to
have virological failure compared to those infected through heterosexual contact. On univariate analysis, patients aged
<50 years without comorbidities were more likely to experience virological failure than those aged ≥50 years with comorbidi-
ties (hazard ratio 1.75, 95% confidence interval (CI) 1.31 to 2.33, p < 0.001). However, the multivariate model showed that
age-related comorbidities were not significant factors for virological failure (hazard ratio 1.31, 95% CI 0.98 to 1.74, p = 0.07).
There were 391 immunological failures, with an incidence of 2.75/100 person-years. On multivariate analysis, those aged
<50 years without comorbidities (p = 0.025) and age <50 years with comorbidities (p = 0.001) were less likely to develop
immunological failure compared to those aged ≥50 years with comorbidities.
Conclusions: In our Asia regional cohort, age-associated comorbidities did not affect virologic outcomes of cART. Among those
with comorbidities, patients <50 years old showed a better CD4 response.
Keywords: HIV; cART; age-associated comorbidity; immunological failure; virological failure; TAHOD (TREAT Asia HIV
Observational Database)
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1 | INTRODUCTION
Combination antiretroviral therapy (cART) has dramatically
improved the survival and quality of life for people living with
HIV [1-3]. A growing proportion of patients are over the age
of 50 years, and by the end of 2013, over four million
individuals older than 50 years were living with HIV infection
worldwide [4]. For instance, in Canada the number of older
adults with HIV has doubled over the past 20 years, and in
Western Europe the estimated number of people living with
HIV aged 50 years and over has almost quadrupled over the
past decade [5,6]. Despite successful cART, many ageing HIV-
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positive patients have developed age-associated comorbidities
such as cardiovascular, metabolic, pulmonary, renal, bone and
malignant diseases, and these are often more prevalent com-
pared with HIV-negative individuals [7,8]. Risk and manage-
ment of comorbidities in ageing adults with HIV will continue
to evolve as treatment improves and life expectancy increases
[5,6].
Polypharmacy is also common in the HIV-positive older
adult population [9,10]. The Swiss HIV cohort study comparing
HIV-positive adults aged ≥50 years with HIV-positive patients
aged <50 years on cART found that older patients were more
likely to receive one or more co-medications compared with
younger patients [11]. This study also determined that older
patients had more frequent potential for drug-to-drug interac-
tions when compared to younger patients. The effects of
polypharmacy may be more substantial in older HIV-positive
persons because of the increased chance of drug-to-drug
interactions [9,12]. It has been shown that older HIV-positive
patients have better adherence to cART than younger patients
[13,14], and this can increase the likelihood of potential drug
interactions. Drug interactions might be associated with a sub-
stantial risk for toxicity, decreased efficacy and subsequent
emergence of drug resistance.
Another paper with the Swiss HIV cohort study investigated
the prevalence of comedications and potential drug-to-drug
interactions within a large HIV cohort, and their effect on
ART efficacy and tolerability [15]. They found potential drug-
to-drug interactions increase with complex ART and comor-
bidities, but no adverse effect was noted on ART efficacy or
tolerability.
Previous studies showed older HIV-positive individuals have
a less robust immune response but, likely due to better adher-
ence, a better virologic response [16-18]. However, multiple
comorbidities among HIV-positive individuals may increase the
potential for polypharmacy and older individuals with comor-
bidities, particularly those with cognitive impairment, may have
difficulty in adhering to complex medication regimens [13].
However, the effects of age-associated comorbidities on the
treatment outcomes of cART are not well known. In this study,
we investigated the effects of age-associated comorbidities on
therapeutic outcomes of cART in HIV-positive adults in Asian
countries.
2 | METHODS
2.1 | Study design and data collection
We analysed data from the TREAT Asia HIV Observational
Database (TAHOD), a prospective, observational cohort study
of HIV-positive adults enrolled from 21 clinical sites, which is
a contributing cohort to IeDEA Asia-Pacific [19]. We selected
eligible subjects for this analysis among patients who were
enrolled in TAHOD from 2003 to 2015. The TAHOD data-
base and methods have been previously described [20]. Due
to the observational nature of the cohort, viral load (VL) and
CD4 testing are not performed on a predefined basis but
depend on the site’s local practices and the patient’s financial
circumstances. Institutional review board approvals were
obtained at all participating sites, the data management and
analysis centre (Kirby Institute, University of New South
Wales, Sydney, Australia), and the coordinating centre (TREAT
Asia/amfAR, Bangkok, Thailand). Patients provided written
informed consent to participate in the TAHOD where
required by local institutional review boards.
2.2 | Definitions
Patients were included in the analysis if they had been on
cART for more than 6 months. Our failure outcomes were
defined to be in-line with the World Health Organization
(WHO) 2016 guidelines [21] as follows: (i) virological failure
was defined as a single VL >1000 copies/mL; (ii) immunologi-
cal failure was defined as CD4 count falling below 250 cells/
lL after a clinical failure, or persistent CD4 levels below
100 cells/lL (two consecutive CD4 counts below 100 cells/lL
within six months). We assumed no treatment failure had
occurred if there was an absence of VL or CD4 count. We uti-
lized a single VL measurement, rather than a second confirma-
tory testing, as the median VL testing frequency in our cohort
was 1 (interquartile range (IQR) 1 to 2) per patient per year.
Patients were included in the virological failure analysis if they
had at least one VL measurement available after six months
on cART. Immunological failure analysis included patients with
pre-cART CD4 count available and at least one CD4 measure-
ment after six months from cART initiation. Both analyses
were censored at four years from cART initiation.
Comorbidities evaluated included hypertension, diabetes,
dyslipidaemia and impaired renal function. Hypertension was
defined as a diastolic blood pressure ≥90 mmHg and/or sys-
tolic blood pressure ≥140 mmHg [22]; diabetes was defined
as a fasting blood glucose level ≥7.0 mmol/L or 126 mg/dL
[23]; dyslipidaemia was defined using any one of the following
four criteria: total cholesterol ≥240 mg/dL, triglyceride
≥200 mg/dL, high-density lipoprotein cholesterol <40 mg/dL,
low-density lipoprotein cholesterol ≥160 mg/dL according to
National Cholesterol Education Programme ATP-III guidelines;
impaired renal function was defined as an estimated glomeru-
lar filtration rate (eGFR) <60 mL/minute by CKD EPI equa-
tion [24].
Patients were grouped into four categories according to
their age and comorbidities: (i) age <50 years with no comor-
bidities, (ii) age <50 years with comorbidities, (iii) age
≥50 years without comorbidities, and (iv) age ≥50 years with
comorbidities. Age-associated comorbidity and cART adher-
ence were included as time-varying variables. Time-fixed
covariates included in the analyses were sex, HIV-1 exposure
risks, baseline CD4 cell count, baseline viral load, cART regi-
men, prior AIDS-defining illness, hepatitis co-infection and
smoking history. Ethnicity was reported descriptively but not
included in the regression analyses due to the inclusion of site
as a stratification variable. Year of cART initiation was not
included in the multivariate model selection due to collinearity
with cART adherence, as our cohort began collecting adher-
ence data from 2011 onwards. However, we assessed the
direction of the hazard ratios (HRs) by adjusting with other
significant covariates in the absence of the adherence vari-
able.
2.3 | Statistical analysis
Cox regression analysis was used to analyse time to first viro-
logical and immunological failure, stratified by clinical site. Risk
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time started six months from cART initiation. Patients who did
not fail in either category were censored on the last date of
VL testing for the virological failure analysis, and of CD4 test-
ing for immunological failure analysis, all within four years
from cART initiation. Sensitivity analyses were performed dis-
aggregating by sex. Data management and statistical analyses
were conducted using SAS software version 9.4 (SAS Institute
Inc., Cary, NC, USA) and STATA software version 14 (STATA
Corp., College Station, TX, USA).
3 | RESULTS
3.1 | Patient characteristics
Table 1 shows the baseline characteristics of patients included
in both the virological and immunological analyses. In the viro-
logical failure analysis, a total of 5411 patients were included
from Cambodia, China, Hong Kong SAR, India, Indonesia,
Japan, Malaysia, the Philippines, Singapore, South Korea, Tai-
wan, Thailand and Vietnam. The median age at cART initiation
was 35 years (IQR 29 to 41), with 66% being aged <50 years
without the presence of co-morbidities prior to cART initia-
tion. Most patients were male (71%) and the majority were
Thai (33%) and Chinese (27%). Heterosexual mode of HIV
exposure was predominant (62%) and the median CD4 cell
count at cART initiation was 130 cells/lL (IQR 40 to 228). Of
the 5411 patients, there were 912 (17%) with virological fail-
ure. The median age was slightly lower at 34 years (IQR 29 to
40) and the median CD4 cell count was 97 cells/lL (IQR 25
to 200).
The immunological failure analysis included 5621 patients in
total, with a similar distribution of characteristics to the viro-
logical failure analysis. The median CD4 testing was two per
patient per year (IQR 1 to 2). There were 391 patients (7%)
who had an immunological failure. For each of the comorbidity
groups, the median CD4 cell count at cART initiation was
116 cells/lL IQR (40 to 209) for age <50 without comorbidi-
ties, 157 cells/lL IQR (47 to 245) for age <50 with comor-
bidities, 116 cells/lL IQR (37 to 217) for age ≥50 years
without comorbidities, and 164 cells/lL IQR (61 to 239) for
age ≥50 years with comorbidities. Of the total patients in
each comorbidity group, the number of patients initiating
cART at CD4 cell count ≤200 cells/lL were 2662/3653
(73%), 894/1449 (62%), 198/285 (69%) and 145/234 (62%)
respectively.
3.2 | Virological failure
Of the 5411 patients included, 1858 (34%) had hypertension,
570 (11%) had diabetes mellitus, 2689 (50%) had dyslipi-
daemia and 353 (7%) had impaired renal function. There were
912 (17%) virological failures reported during 11,814.84 per-
son-years of follow-up, with an incidence rate of 7.72 per 100
person-years (/100PYS) (Table 2). The median time from cART
initiation up to date of first virological failure or date of last
VL test was three years (IQR 1.7 to 3.7). In the univariate
analyses, having age-related comorbidities (p < 0.001), cART
adherence (p < 0.001), mode of HIV exposure (p < 0.001),
pre-ART VL (p = 0.029), pre-ART CD4 (p < 0.001), initial ART
regimen (p = 0.097), hepatitis C co-infection (p = 0.055), prior
AIDS diagnosis (p = 0.018) and ever smoked (p = 0.051) were
associated with virological failure, and were thus entered into
the multivariate model. Those with adherence <95%
(HR = 0.15, 95% confidence interval (CI) 0.10 to 0.21,
p < 0.001) compared to adherence ≥95% and a higher CD4
count at start of cART (CD4 101 to 200 cells/lL, HR = 0.70,
95% CI 0.57 to 0.85; CD4 > 200 cells/lL, HR = 0.61, 95% CI
0.50 to 0.74, p < 0.001) were less likely to have virological
failure. Those who acquired HIV through intravenous drug use
were more likely to fail compared to a heterosexual mode of
exposure (HR = 1.47, 95% CI 1.14 to 1.88, p = 0.003).
Although not statistically significant, patients aged ≥50 years
with comorbidities performed slightly better than the other
three groups.
To determine the effects of the year of cART initiation on
virological failure and to avoid collinearity with the adherence
variable, we included year of cART initiation in the multivari-
ate model without adjusting for adherence. As expected, later
years of cART initiation were associated with decreased haz-
ard for failure (2003 to 2005: HR = 0.82, 95% CI 0.67 to
1.00, p = 0.052; 2006 to 2009: HR = 0.50, 95% CI 0.41 to
0.62, p < 0.001; and 2010 to 2014: HR = 0.38, 95% CI 0.29
to 0.49, p < 0.001) compared to years prior to 2003.
3.3 | Immunological failure
The rate of immunological failure was 2.75/100 PYS (Table 3).
Of the 5621 patients included, there were 391 (7%) patients
who experienced immunological failure during 14,196 person-
years of follow-up. The median time from cART initiation was
3.5 years (IQR 2.5 to 3.8). There were 2105 (37%) patients
with hypertension, 607 (11%) with diabetes, 2748 (49%) with
dyslipidaemia and 404 (7%) with impaired renal function.
In the multivariate analyses, those aged <50 years without
comorbidities (HR = 0.66, 95% CI 0.46 to 0.95, p = 0.025)
and aged <50 years with comorbidities (HR = 0.54, 95% CI
0.38 to 0.76, p = 0.001) were less likely to develop immuno-
logical failure compared to those patients aged ≥50 years with
comorbidities. Other factors associated with a reduction in
hazard for failure were cART adherence ≥95% (HR = 0.16,
95% CI 0.09 to 0.29, p < 0.001) compared to adherence
<95%, female sex (HR = 0.60, 95% CI 0.46 to 0.79,
p < 0.001), homosexual mode of exposure (HR = 0.52, 95%
CI 0.34 to 0.79, p = 0.002) compared to heterosexual mode
of exposure, and higher CD4 count (CD4 51 to 100 cells/lL:
HR = 0.45, 95% CI 0.34 to 0.60; CD4 101 to 200 cells/lL:
HR = 0.24, 95% CI 0.17 to 0.32; and CD4 > 200 cells/lL:
HR = 0.11, 95% CI 0.07 to 0.16, all p < 0.001) compared to
CD4 ≤ 50 cells/lL.
When year of cART initiation was included in the final multi-
variate model in place of the adherence variable, we saw
decreasing hazard for failure in later years (2003 to 2005:
HR = 0.74, 95% CI 0.54 to 1.01, p = 0.058; 2006 to 2009:
HR = 0.56, 95% CI 0.41 to 0.77, p < 0.001; and 2010 to
2014: HR = 0.28 95% CI 0.18 to 0.44, p < 0.001) compared
to years prior to 2003.
To examine patterns of CD4 changes in our patient group,
we plotted the median change in CD4 cell count for each of
our comorbidities group. Figure 1 shows median CD4
increases at each six-month interval, categorized by comorbid-
ity and age at cART initiation. Patients aged ≥50 years were
shown to have slower increases in CD4 cell counts compared
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Table 1. Patient characteristics
Virological failure Immunological failure
Total patients
included = 5411 (100%)
Total patients with
VL failures = 912 (17%)
Total patients
included = 5621 (100%)
Total patients with
immunological
failures = 391 (7%)
Age at cART initiation (years) Median = 35,
IQR (29 to 41)
Median = 34,
IQR (29 to 40)
Median = 35,
IQR (29 to 41)
Median = 35,
IQR (30 to 42)
≤30 1616 (30) 317 (35) 1692 (30) 105 (27)
31 to 40 2302 (43) 388 (43) 2417 (43) 168 (43)
41 to 50 1040 (19) 143 (16) 1065 (19) 71 (18)
>50 453 (8) 64 (7) 447 (80) 47 (12)
Year of cART initiation
<2003 699 (13) 204 (22) 627 (11) 87 (22)
2003 to 2005 1167 (22) 221 (24) 1186 (21) 113 (29)
2006 to 2009 2077 (38) 279 (31) 2207 (39) 139 (36)
2010 to 2014 1468 (27) 208 (23) 1601 (28) 52 (13)
Pre-cART age-related comorbidities
Age <50 years
without comorbidities
3559 (66) 623 (68) 3653 (65) 260 (66)
Age <50 years
with comorbidities
1335 (25) 219 (24) 1449 (26) 81 (21)
Age ≥50 years
without comorbidities
305 (6) 41 (4) 285 (5) 27 (7)
Age ≥50 years
with comorbidities
212 (4) 29 (3) 234 (5) 23 (6)
Sex
Male 3839 (71) 679 (74) 3886 (69) 316 (81)
Female 1572 (29) 233 (26) 1735 (31) 75 (19)
Ethnicity
Caucasian 19 (0.4) 2 (0.2) 16 (0.3) 1 (0.3)
Chinese 1448 (27) 312 (34) 1284 (23) 112 (29)
Filipino 211 (4) 24 (3) 241 (4) 8 (2)
Indian 503 (9) 87 (10) 734 (13) 55 (14)
Indonesian 236 (4) 68 (7) 405 (7) 53 (14)
Japanese 222 (4) 11 (1) 68 (1) 2 (10
Khmer 218 (4) 22 (2) 436 (8) 50 (13)
Korean 241 (4) 60 (7) 216 (4) 12 (3)
Malay 96 (2) 29 (3) 80 (1) 8 (2)
Thai 1788 (33) 193 (21) 1613 (29) 59 (15)
Vietnamese 401 (7) 103 (11) 502 (9) 31 (8)
Other 28 (1) 1 (0.1) 26 (0.5) 0 (0)
HIV Exposure
Heterosexual contact 3355 (62) 514 (56) 3736 (66) 290 (74)
Homosexual contact 1385 (26) 218 (24) 1125 (20) 39 (10)
Injecting drug use 289 (5) 103 (11) 335 (6) 38 (10)
Other/Unknown 382 (7) 77 (8) 425 (8) 24 (6)
Pre-cART Viral
Load (copies/mL)
Median = 98,000, IQR
(27,700 to 290,000)
Median = 110,000,
IQR (33,739 to 390,000)
Median = 99,180,
IQR (27,574 to 290,000)
Median = 150,000,
IQR (42,089
to 400,000)
<100,000 1570 (29) 226 (25) 1583 (28) 68 (17)
≥100,000 1529 (28) 263 (29) 1561 (28) 99 (25)
Missing 2312 (43) 423 (46) 2477 (44) 224 (57)
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to patients <50 years. At four years from cART initiation,
patients aged <50 years with comorbidities showed the big-
gest median change in CD4 cell count, while the median
change in the CD4 cell count was the smallest for patients
aged ≥50 years with comorbidities. The small decrease in
CD4 count in the age ≥50 years with the comorbidities group
at the fourth year could be attributed to the small sample size
present at that time point (76 patients).
3.4 | Sensitivity analyses
Factors associated with virological failure in males and females
are shown in Table S1. cART adherence <95% was associated
with failure in both sexes; however, higher CD4 cell count at
cART initiation was associated with reduced hazard for failure
in males, but this was not statistically significant in females.
Table S2 reports risk factors for immunological failure in
males and females. Age <50 with or without comorbidities,
cART adherence ≥95%, and higher pre-cART CD4 cell count
were associated with reductions in HRs in both males and
females. Females who have never smoked were less likely to
develop immunological failure, however this association was
not evident in males. Overall the effects of the age-related
comorbidity variable in the main analyses and in the sensitivity
analyses remained similar suggesting that regardless of sex,
those aged ≥50 years with comorbidities had worse immuno-
logical outcomes than their younger counterpart either with
or without comorbidities.
4 | DISCUSSION
We hypothesized that age-associated comorbidities may wor-
sen therapeutic outcomes of cART, because of the risk of
Table 1. (Continued)
Virological failure Immunological failure
Total patients
included = 5411 (100%)
Total patients with
VL failures = 912 (17%)
Total patients
included = 5621 (100%)
Total patients with
immunological
failures = 391 (7%)
Pre-cART CD4 (cells/lL) Median = 130,
IQR (40 to 228)
Median = 97,
IQR (28 to 200)
Median = 127,
IQR (40 to 223)
Median = 30,
IQR (12 to 73)
≤50 1329 (25) 266 (29) 1642 (29) 254 (65)
51 to 100 636 (12) 108 (12) 801 (14) 56 (14)
101 to 200 1143 (21) 177 (19) 1456 (26) 53 (14)
>200 1463 (27) 182 (20) 1722 (31) 28 (7)
Missing 840 (16) 179 (20) 0 0
Initial cART category
NRTI+NNRTI 4389 (81) 712 (78) 4845 (86) 343 (88)
NRTI+PI 930 (17) 182 (20) 701 (12) 45 (12)
Other combination 92 (2) 18 (2) 75 (1) 3 (1)
Hepatitis B co-infection
Negative 3897 (72) 622 (68) 3903 (69) 287 (73)
Positive 457 (8) 76 (8) 463 (8) 38 (10)
Not tested 1057 (20) 214 (23) 1255 (22) 66 (17)
Hepatitis C co-infection
Negative 3635 (67) 555 (61) 3599 (64) 272 (70)
Positive 513 (9) 126 (14) 532 (9) 49 (13)
Not tested 1263 (23) 231 (25) 1490 (27) 70 (18)
Prior AIDS diagnosis
No 3478 (64) 534 (59) 3571 (64) 177 (45)
Yes 1933 (36) 378 (41) 2050 (36) 214 (55)
Ever smoked cigarettes
No 2138 (40) 302 (33) 2103 (37) 106 (27)
Yes 1535 (28) 275 (30) 1454 (26) 109 (28)
Unknown 1738 (32) 335 (37) 2064 (37) 176 (45)
cART adherence
Always ≥95% 2357 (44) 211 (23) 2598 (46) 60 (15)
Ever <95% 253 (5) 53 (6) 270 (5) 16 (4)
Not reported 2801 (52) 648 (71) 2753 (49) 315 (81)
cART, combination antiretroviral therapy; IQR, interquartile range; VL, viral load.
Ahn MY et al. Journal of the International AIDS Society 2019, 22:e25228
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25228/full | https://doi.org/10.1002/jia2.25228
5
Table 2. Factors associated with virological failure
No patients
Follow-up
(years)
No of
failures
Failure rate
(per 100
person-years)
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Total 5411 11,814.84 912 7.72
Age-related comorbidities <0.001 0.089
Age <50 years
without comorbidities
~ 4420.08 441 9.98 1.75 (1.31, 2.33) <0.001 1.31 (0.98, 1.74) 0.070
Age <50 years
with comorbidities
~ 5883.95 381 6.48 1.19 (0.90, 1.58) 0.216 1.10 (0.83, 1.45) 0.514
Age ≥50 years
without comorbidities
~ 375.20 32 8.53 1.54 (0.99, 2.40) 0.054 1.11 (0.71, 1.73) 0.645
Age ≥50 years
with comorbidities
~ 1135.40 58 5.11 1 1
cART adherence
<95% ~ 175.01 42 24.00 1 1
≥95% ~ 5923.81 267 4.51 0.14 (0.10, 0.20) <0.001 0.15 (0.10, 0.21) <0.001
Missing ~ 5716.03 603 10.55
Sex
Male 3839 8291.98 679 8.19 1 1
Female 1572 3522.86 233 6.61 0.97 (0.83, 1.14) 0.727 1.04 (0.87, 1.23) 0.686
HIV exposure <0.001 0.019
Heterosexual contact 3355 7614.28 514 6.75 1 1
Homosexual contact 1385 3016.02 218 7.23 0.80 (0.65, 0.99) 0.041 1.01 (0.81, 1.25) 0.931
Injecting drug use 289 494.11 103 20.85 1.57 (1.22, 2.01) <0.001 1.47 (1.14, 1.88) 0.003
Other/Unknown 382 690.43 77 11.15 1.08 (0.83, 1.42) 0.550 1.19 (0.90, 1.56) 0.217
Pre-cART viral load (copies/lL)
<100,000 1570 3627.15 226 6.23 1 1
≥100,000 1529 3369.37 263 7.81 1.22 (1.02, 1.46) 0.029 1.05 (0.87, 1.26) 0.630
Missing 2312 4818.32 423 8.78
Pre-cART CD4 (cells/lL) <0.001 <0.001
≤50 1329 2804.11 266 9.49 1 1
51 to 100 636 1388.94 108 7.78 0.84 (0.67, 1.06) 0.139 0.83 (0.66, 1.04) 0.111
101 to 200 1143 2546.00 177 6.95 0.69 (0.57, 0.84) <0.001 0.70 (0.57, 0.85) <0.001
>200 1463 3136.82 182 5.80 0.55 (0.45, 0.67) <0.001 0.61 (0.50, 0.74) <0.001
Missing 840 1938.96 179 9.23
Initial cART category 0.097 0.667
NRTI+NNRTI 4389 9408.65 712 7.57 1 1
NRTI+PI 930 2193.97 182 8.30 1.24 (1.00, 1.52) 0.048 0.98 (0.79, 1.21) 0.839
Other combination 92 212.22 18 8.48 1.34 (0.83, 2.18) 0.230 1.23 (0.76, 1.99) 0.409
Hepatitis B co-infection
Negative 3897 8672.08 622 7.17 1 1
Positive 457 1023.49 76 7.43 0.98 (0.77, 1.24) 0.850 0.89 (0.70, 1.14) 0.355
Not tested 1057 2119.27 214 10.10
Hepatitis C co-infection
Negative 3635 8261.66 555 6.72 1 1
Positive 513 980.51 126 12.85 1.24 (1.00, 1.54) 0.055 0.99 (0.77, 1.25) 0.908
Not tested 1263 2572.67 231 8.98
Prior AIDS diagnosis
No 3478 7593.57 534 7.03 1 1
Yes 1933 4221.28 378 8.95 1.18 (1.03, 1.36) 0.018 0.95 (0.81, 1.10) 0.490
Ahn MY et al. Journal of the International AIDS Society 2019, 22:e25228
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25228/full | https://doi.org/10.1002/jia2.25228
6
polypharmacy and additive negative effects of these health
conditions. However, our results showed that presence of
age-associated comorbidities did not affect virological out-
comes of cART, and patients <50 years with comorbidities
had better immunological outcomes compared with patients
≥50 years with comorbidities.
The prevalence of age-related comorbidities in this study
population was similar to the results from other studies. The
prevalence of dyslipidaemia among HIV-positive populations dif-
fers depending on the methodology and patient population
studied, ranging from 20% to 80% [25]. According to the Swiss
HIV Cohort study, the prevalence of hypertension and diabetes
mellitus were 56.3% and 4.1% respectively [1]. In that study,
the eGFR (calculated by the Modification of Diet in Renal Dis-
ease Study equation) of older HIV-positive participants was
lower than that of younger HIV-positive patients. HIV-positive
patients may have greater risk of non-infectious comorbidities
than the general population, because of the effects of HIV itself,
prevalent risk factors, and antiretroviral medications [26]. The
treatment of older HIV-positive patients is complicated by pre-
existing comorbid conditions, including cardiovascular, hepatic
and metabolic complications that may be exacerbated by the
effects of HIV infection per se, immunodeficiency and metabolic
and other adverse effects of combination antiretroviral therapy
[27,28]. Synergistic deleterious effects of chronic immune acti-
vation on the course of HIV infection with the immune senes-
cence of ageing may promote this accelerated course [27].
A study from Italy showed that age-related non-infectious
comorbidities were more common among HIV-positive
patients than in the general population [26]. They performed a
case–control study involving ART-experienced HIV-positive
patients treated from 2002 through to 2009. These patients
were compared with age-, sex- and race-matched adult con-
trols from the general population. The prevalence of hyperten-
sion, renal failure and diabetes mellitus of the HIV group
<50 years were 13.2%, 3.78% and 6.17% respectively. The
rates were greater than the general population.
Multiple studies have demonstrated that, despite successful
ART and viral suppression, immune recovery is less robust
with increasing age, highlighting the importance of early diag-
nosis and treatment of HIV [16,29-32]. Consistent with previ-
ous studies, patients aged ≥50 years with comorbidities in our
study had a greater rate of immunological failure compared to
patients <50 years with comorbidities. As shown in Figure 1,
patients aged ≥50 years were shown to have slower increases
in CD4 cell counts compared to patients <50 years. This is
consistent with previous studies as well. The poorer immune
recovery in older populations could be caused in part by
decreased thymic function in these groups [31]. In addition,
late diagnosis can be more frequent in older populations, and
low baseline CD4 cells might affects the immunological
responses. However, in our study cohort, the highest propor-
tion of those who initiated ART late was in the age <50 years
without co-morbidities group, and the median CD4 cell count
at baseline was lowest for those age <50 years without co-
morbidities and those age ≥50 years without co-morbidities.
Nevertheless, older patients derive substantial benefit from
cART despite having a less robust immunological response
than expected given their adherence to therapy and excellent
virological responses [27]. cART provides substantial benefit
for older and younger HIV-positive patients [33], and older
patients are more likely to achieve virological control of HIV
replication [34,35] and less likely to develop subsequent viro-
logical breakthrough [34], findings that correlate with better
adherence to therapy by older patients [35]. Consistent with
previous studies, our study showed that older patients had
similar virological outcomes compared with younger patients.
Overall, the effects of the age-related comorbidity variables
in the main analyses and in the sensitivity analyses remained
similar, suggesting that regardless of sex, those aged
≥50 years with comorbidities had worse immunological out-
comes than their younger counterparts either with or without
comorbidities.
The limitations of the study included the presence missing
data. As TAHOD is an observational cohort, data collection
depends entirely on the standard of care at each individual
site. Patients with good clinic attendance may have more fre-
quent comorbidity testing which may lead to earlier or more
frequent diagnosis of a comorbidity. Patients with poor clinic
attendance may also have these comorbidities present but not
detected. As the cohort does not impose specific study proce-
dures or treatment interventions, the study results should be
interpreted with this in mind. The cutoff points for virologic
and immunologic failures may not necessarily be relevant for
individual patient management, but the failure definition is in
line with current WHO guidelines for general clinical practice.
In addition, the comorbidity variable was defined according to
the availability of our data. We were not able to assess the
Table 2. (Continued)
No patients
Follow-up
(years)
No of
failures
Failure rate
(per 100
person-years)
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Ever smoked cigarettes
No 2138 4891.63 302 6.17 1 1
Yes 1535 3466.78 275 7.93 1.18 (1.00, 1.40) 0.051 1.05 (0.88, 1.24) 0.597
Unknown 1738 3456.43 335 9.69
~ age-related comorbidity and cART adherence are time-updated variables. Missing values were included in the regression analyses; however, glo-
bal p-values were tested for heterogeneity excluding missing categories. Significant p-values are highlighted in bold. Variables not associated with
significant p-values are presented in the final table adjusted for the variables with significant p-values. CI, confidence interval; HR, Hazard ratio;
NRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non-nucleoside reverse-transcriptase inhibitor; PI, Protease inhibitor.
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effects of other comorbidities, as we were limited to the data
variables being captured in our cohort. Furthermore, our
cohort sites are generally urban referral centres. Patients are
selected for enrolment based on the likelihood of remaining in
care. Therefore, the generalizability of the reported findings is
limited.
Table 3. Factors associated with immunological failure
No patients
Follow-up
(years)
No of
failures
Failure rate
(per 100
person-years)
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Total 5621 14,196 391 2.75
Age-related comorbidities 0.003 0.005
Age <50 years
without comorbidities
~ 5310 185 3.48 0.88 (0.62, 1.25) 0.480 0.66 (0.46, 0.95) 0.025
Age <50 years
with comorbidities
~ 7243 152 2.10 0.62 (0.43, 0.88) 0.007 0.54 (0.38, 0.76) 0.001
Age ≥50 years
without comorbidities
~ 365 13 3.56 1.01 (0.54, 1.91) 0.968 0.74 (0.39, 1.40) 0.354
Age ≥50 years
with comorbidities
~ 1279 41 3.21 1 1
cART adherence
<95% ~ 222 14 6.30 1 1
≥95% ~ 7232 80 1.11 0.15 (0.09, 0.28) <0.001 0.16 (0.09, 0.29) <0.001
Missing ~ 6742 297 4.41
Sex
Male 3886 9644 316 3.28 1 1
Female 1735 4552 75 1.65 0.51 (0.40, 0.67) <0.001 0.60 (0.46, 0.79) <0.001
HIV exposure <0.001 0.022
Heterosexual contact 3736 9654 290 3.00 1 1
Homosexual contact 1125 2764 39 1.41 0.36 (0.24, 0.55) <0.001 0.52 (0.34, 0.79) 0.002
Injecting drug use 335 761 38 5.00 1.12 (0.75, 1.67) 0.570 0.86 (0.57, 1.31) 0.490
Other/Unknown 425 1017 24 2.36 0.69 (0.44, 1.08) 0.106 0.76 (0.48, 1.21) 0.248
Pre-cART viral load (copies/mL)
<100,000 1583 4023 68 1.69 1 1
≥100,000 1561 3944 99 2.51 1.37 (1.00, 1.87) 0.051 0.84 (0.61, 1.16) 0.293
Missing 2477 6229 224 3.60
Pre-cART CD4 (cells/lL) <0.001 <0.001
≤50 1642 3974 254 6.39 1 1
51 to 100 801 2046 56 2.74 0.44 (0.33, 0.59) <0.001 0.45 (0.34, 0.60) <0.001
101 to 200 1456 3810 53 1.39 0.21 (0.16, 0.29) <0.001 0.24 (0.17, 0.32) <0.001
>200 1722 4366 28 0.64 0.09 (0.06, 0.14) <0.001 0.11 (0.07, 0.17) <0.001
Initial cART category 0.614 0.923
NRTI+NNRTI 4845 12,163 343 2.82 1 1
NRTI+PI 701 1851 45 2.43 1.20 (0.82, 1.77) 0.343 0.93 (0.63, 1.36) 0.708
Other combination 75 183 3 1.64 0.91 (0.28, 2.90) 0.872 0.89 (0.28, 2.86) 0.845
Hepatitis B co-infection
Negative 3903 10,022 287 2.86 1 1
Positive 463 1209 38 3.14 1.20 (0.86, 1.69) 0.286 1.01 (0.71, 1.42) 0.977
Not tested 1255 2965 66 2.23
Hepatitis C co-infection
Negative 3599 9324 272 2.92 1 1
Positive 532 1306 49 3.75 1.11 (0.79, 1.55) 0.555 0.90 (0.61, 1.34) 0.613
Not tested 1490 3565 70 1.96
Prior AIDS diagnosis
No 3571 9083 177 1.95 1 1
Yes 2050 5113 214 4.19 1.78 (1.44, 2.19) <0.001 0.85 (0.68, 1.07) 0.164
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5 | CONCLUSIONS
Age associated comorbidities did not affect virological out-
comes of cART, and older patients with comorbidities were
more likely to experience immunological failure compared to
those aged <50 years.
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Table 3. (Continued)
No patients
Follow-up
(years)
No of
failures
Failure rate
(per 100
person-years)
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Ever smoked cigarettes
No 2103 5531 106 1.92 1 1
Yes 1454 3845 109 2.84 1.23 (0.93, 1.61) 0.142 0.87 (0.65, 1.17) 0.366
Unknown 2064 4820 176 3.65
~ age-related comorbidity and cART adherence are time-updated variables. Missing values were included in the regression analyses, however glo-
bal p-values were tested for heterogeneity excluding missing categories. Significant p-values are highlighted in bold. Variables not associated with
significant p-values are presented in the final table adjusted for the variables with significant p-values. CI, confidence interval; HR, hazard ratio;
NRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non-nucleoside reverse-transcriptase inhibitor; PI, Protease inhibitor.
Figure 1. Median changes in CD4 cell count from cART initiation.
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